Results 231 to 240 of about 22,201 (271)

Correction: Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund Support. [PDF]

Harm Reduct J
Stuikyte R, Varentsov I, Cook C, Dvoriak S.   +3 more
europepmc   +1 more source

Multidisciplinary Therapy to Target Obesity and Its Complications in Adult Population: A Narrative Review

Obesity Reviews, Volume 27, Issue 7, July 2026.
ABSTRACT Obesity as a chronic and multifactorial disease requires a multidisciplinary team acting together in a holistic multitarget intervention. Multidisciplinary therapy targeting obesity and its complications includes physical exercise, nutritional, and behavior counseling.
Ana Raimunda Dâmaso, Flávia Campos Corgosinho, Deborah Cristina Landi Masquio, Nayra Figueiredo, Fabiana Kattah, Cintia Cercato, Lian Tock, Raquel Munhoz da Silveira Campos   +7 more
wiley   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, Volume 36, Issue 44, 1 June 2026.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study. [PDF]

CNS Drugs
Lang-Illievich K, Lang J, Rumpold-Seitlinger G, Dorn C, Brenna CTA, Klivinyi C, Bornemann-Cimenti H.   +6 more
europepmc   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Expanding the Reach of Opioid Agonist Therapy—Lessons for Indigenous Communities

JAMA Network Open
openaire   +2 more sources

Redirecting Alzheimer's disease therapeutics: Multitarget drugs and complementary non‐pharmacological strategies

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder driven by intersecting pathological processes. Persistent attrition in AD drug‐development pipelines highlights the limited clinical impact of single‐target therapies and has increased interest in multi‐target approaches acting on shared biological hubs.
Humberto Martínez‐Orozco, Jesús Andrade‐Guerrero, Nelly Jovana Pastén‐Castrejón, Chryslaine Rodríguez‐Tanty, Sofía Y Diaz‐Miranda   +4 more
wiley   +1 more source

Characterizing treatment initiation with central nervous system–active polypharmacy among adults with dementia

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract INTRODUCTION Central nervous system (CNS) –active polypharmacy, defined as concurrent use of antidepressants, antipsychotics, anti‐seizure medications, benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, opioids, or skeletal muscle relaxants for ≥ 31 consecutive days, poses significant risks patients with dementia.
Donovan T. Maust, Rachel C. Davis, Julie Strominger, Steven C. Marcus, Hyungjin Myra Kim, Tanner Caverly, Frederic C. Blow, Lauren P. Wallner, Sarah Krein, Sarah E. Vordenberg   +9 more
wiley   +1 more source

Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. [PDF]

PLOS Glob Public Health
Bromberg DJ, Madden LM, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice FL.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The duration dilemma in opioid agonist therapy

Journal of Opioid Management, 2021
Objective: Studies dating back to 1964 consistently support the effectiveness of methadone as a maintenance treatment for opioid use disorder (OUD), and since 2003, the effectiveness of buprenorphine. Short-term detoxification has not proven to be an effective treatment, as it results in high relapse rates when compared with maintenance treatment with ...
Anjali, Dhanda, Edwin A, Salsitz
openaire   +2 more sources